K. Petty

发表

Tissue- and cell-specific distribution of proteins that interact with the human thyroid hormone receptor-β

K. Petty, 1995, Molecular and Cellular Endocrinology.

In Vitro and in Vivo Properties of 3-tert-Butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy)-pyrazolo[1,5-d]-[1,2,4]triazine (MRK-016), a GABAA Receptor α5 Subtype-Selective Inverse Agonist

A. D. Rodrigues, K. Gingrich, G. Dawson, 2009, Journal of Pharmacology and Experimental Therapeutics.

In Vitro and in Vivo Properties of 3-tert-Butyl-7-(5-methylisoxazol-

A. D. Rodrigues, K. Gingrich, G. Dawson, 2009 .

Double-blind crossover study to assess potential differences in cytochrome P450 3A4 activity in healthy subjects receiving ondansetron plus dexamethasone, with and without aprepitant

W. Kraft, H. Greenberg, D. Dean, 2011, Cancer Chemotherapy and Pharmacology.

Lack of Effect of Aprepitant on Hydrodolasetron Pharmacokinetics in CYP2D6 Extensive and Poor Metabolizers

P. Lupinacci, T. Rushmore, E. Pequignot, 2006, Journal of clinical pharmacology.

Metal‐Chelate Affinity Chromatography

K. Petty, 1996, Current protocols in molecular biology.

Molecular profiling and gene expression analysis in cutaneous sarcoidosis: the role of interleukin-12, interleukin-23, and the T-helper 17 pathway.

M. Mascelli, E. Barnathan, M. Judson, 2012, Journal of the American Academy of Dermatology.

Functional characterization and receptor binding studies of the malic enzyme thyroid hormone response element.

B. Desvergne, V. Nikodem, K. Petty, 1991, The Journal of biological chemistry.

Secondary effect of aldosterone on Na-KATPase activity in the rabbit cortical collecting tubule.

J. Kokko, K. Petty, D. Marver, 1981, The Journal of clinical investigation.

Pharmacokinetics of Aprepitant After Single and Multiple Oral Doses in Healthy Volunteers

S. Waldman, T. Bradstreet, P. Rothenberg, 2006, Journal of clinical pharmacology.

Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone

C. Lines, P. Deutsch, M. Goldberg, 2003, Clinical pharmacology and therapeutics.

Sputum induction with hypertonic saline reduces fractional exhaled nitric oxide in chronic smokers and non-smokers.

M. D. de Kam, Z. Diamant, K. Petty, 2010, Respiratory medicine.

Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients

V. Cocquyt, D. Panebianco, P. Nygren, 2005, Cancer Chemotherapy and Pharmacology.

Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects.

S. Waldman, W. Kraft, H. Greenberg, 2003, Clinical therapeutics.

Identification of a thyroid hormone response element in the malic enzyme gene.

B. Desvergne, T. Mitsuhashi, V. Nikodem, 1990, The Journal of biological chemistry.

Effects of enteric‐coated, low‐dose aspirin on parameters of platelet function

J. Arnout, K. Gottesdiener, A. van Hecken, 2002, Alimentary pharmacology & therapeutics.

Safety, tolerability and pharmacokinetics of a human anti-interleukin-13 monoclonal antibody (CNTO 5825) in an ascending single-dose first-in-human study.

M. Loza, H. Davis, I. Nnane, 2013, British journal of clinical pharmacology.

Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant

Gunnar Antoni, Jarmo Hietala, Bengt Långström, 2004, Biological Psychiatry.

The Oral NK1 Antagonist Aprepitant for Prevention of Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy

K. Horgan, R. Wit, P. Hesketh, 2005 .

Metal-chelate affinity chromatography.

K. Petty, 2001, Current Protocols in Protein Science.

Pharmacokinetics and Safety of Golimumab in Healthy Chinese Subjects Following a Single Subcutaneous Administration in a Randomized Phase I Trial

Y. Lv, Honghui Zhou, Zhenhua Xu, 2013, Clinical Drug Investigation.

Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open-label, randomized study.

B. Frederick, Honghui Zhou, Zhenhua Xu, 2012, Clinical therapeutics.

Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe

C. Lines, M. Goldberg, J. McCrea, 2003, Clinical pharmacology and therapeutics.

Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin

P. Rothenberg, A. Bergman, D. Panebianco, 2005, European Journal of Clinical Pharmacology.

Evaluation of Potential Inductive Effects of Aprepitant on Cytochrome P450 3A4 and 2C9 Activity

T. Bradstreet, Yih Lee, K. Petty, 2004, Journal of clinical pharmacology.

Comparison of the Pharmacokinetics of Subcutaneous Ustekinumab between Chinese and Non-Chinese Healthy Male Subjects across Two Phase 1 Studies

B. Frederick, Honghui Zhou, J. Marini, 2013, Clinical Drug Investigation.

Dominant inheritance of resistance to thyroid hormone not linked to defects in the thyroid hormone receptor alpha or beta genes may be due to a defective cofactor.

T. Nagaya, H. Seo, Y. Hayashi, 1996, The Journal of clinical endocrinology and metabolism.

Pharmacokinetics of Etoricoxib in Patients with Hepatic Impairment

C. Matthews, K. Lasseter, E. Woolf, 2003, Journal of clinical pharmacology.

Placebo‐ and Amitriptyline‐Controlled Evaluation of Central Nervous System Effects of the NK1 Receptor Antagonist Aprepitant and Intravenous Alcohol Infusion at Pseudo‐Steady State

J. V. van Gerven, D. Tatosian, Diana Selverian, 2013, Journal of clinical pharmacology.

Effect of Aprepitant on the Pharmacokinetics of Intravenous Midazolam

W. Kraft, H. Greenberg, Diana Selverian, 2007, Journal of clinical pharmacology.

Lack of effect of aprepitant on the pharmacokinetics of hydrodolasetron in CYP2D6 extensive and poor metabolizers

E. Pequignot, K. Petty, X. Li, 2005 .

Metal‐Chelate Affinity Chromatography

K. Petty, 1998, Current protocols in neuroscience.

Lack of Effect of Aprepitant on Digoxin Pharmacokinetics in Healthy Subjects

M. Goldberg, M. Feuring, M. Wehling, 2003 .

Lack of effect of aprepitant on digoxin pharmacokinetics in healthy subjects

M. Goldberg, M. Feuring, M. Wehling, 2003, Journal of clinical pharmacology.

A TATA binding protein-associated factor functions as a coactivator for thyroid hormone receptors.

D. Thomas, K. Petty, Y. Krimkevich, 1996, Molecular endocrinology.

Pharmacokinetics and safety of sirukumab following a single subcutaneous administration to healthy Japanese and Caucasian subjects.

Y. Tsukamoto, Honghui Zhou, Zhenhua Xu, 2013, International journal of clinical pharmacology and therapeutics.

Hyperglycemia Associated with Paroxetine

K. Petty, 1996, Annals of Internal Medicine.

Pharmacokinetics of Etoricoxib in Patients with Renal Impairment

S. Swan, C. Matthews, T. Marbury, 2004, Journal of clinical pharmacology.

Effect of Impaired Renal Function and Haemodialysis on the Pharmacokinetics of Aprepitant

T. Bradstreet, S. Swan, A. Bergman, 2005, Clinical pharmacokinetics.

Drug Metabolism Human Liver Aldehyde Oxidase: Inhibition by 239 Drugs 7

R. Obach, M. Farré, S. Szefler, 2004 .